Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	120.10M
Revenue (ttm)	9.94M
Net Income (ttm)	-164.57M
Shares Out	26.45M
EPS (ttm)	-5.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,156
Open	4.670
Previous Close	4.720
Day's Range	4.400 - 4.725
52-Week Range	2.090 - 8.170
Beta	1.78
Analysts	Strong Buy
Price Target	14.33 (+215.64%)
Earnings Date	May 8, 2024

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 2016
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRS

Financial Performance

In 2023, SYRS's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for SYRS stock is "Strong Buy." The 12-month stock price forecast is $14.33, which is an increase of 215.64% from the latest price.

Price Target

$14.33

(215.64% upside)

Analyst Consensus: Strong Buy